MONTCO.Today on MSN1 天
Plymouth Meeting’s Harmony Biosciences Pivots After FDA Rejects Wakix for Sleep Disorder
Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug ...
The Pharma Letter4 天
Fragile X syndrome market to quadruple to $111.9 million in USA and Germany by 2030
According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...